Ticarcillin was used in combination with either cephalothin or gentamicin as initial empiric antibiotic therapy for 127 patient trials of suspected infection in granulocytopenic cancer patients. Bacteremia was present in 20%, nonbacteremic microbiologically documented infections in 21%, clinically documented infections in 23%, and possible infections in 5%; infection was doubtful in 31%. Although Staphylococcus aureus was the most common single organism isolated (23%), gram-negative bacilli accounted for 54% of all pathogens. Both antibiotic regimens were highly efficacious, with complete resolution in 46% of bacteremias, 88% of nonbacteremic microbiologically documented infections, and 95% of clinically documented infections. Among bacteremias, 8 of 9 caused by S. aureus but only 4 of 15 (27%) caused by gram-negative bacilli were completely resolved with these antibiotic combinations. Reasons for nonresponse in bacteremias were persistent granulocytopenia, mixed infection and, in two patients, antibiotic-resistant organisms. Toxicities other than hypokalemia were minimal. Although the rate of further infections was high overall (18/127), only one occurred among the 39 patients with <4 days of antibiotic therapy. Ticarcillin in combination with either cephalothin or gentamicin was effective as initial empiric therapy of suspected infection in granulocytopenic cancer patients.
Despite advances in preventive technique (23) , serious infections continue to occur in granulocytopenic cancer patients (6, 13) . Prompt empiric use of broad-spectrum bactericidal antibiotics in recent years has substantially reduced the morbidity and mortality of infection in this patient population (5-7, 10, 13-17, [24] [25] [26] 29 (5-7, 10, 13-15, 17, [24] [25] [26] 29 ; Greene et al., Ann. Intern. Med. 78:825-826). A new semisynthetic penicillin, ticarcillin (a-carboxyl-3-thienylmethyl penicillin), has been introduced for investigational use (1) . Ticarcillin is quite similar to carbenicillin in structure and activity; it is more active than carbenicillin on a milligramper-milligram basis against most strains of P. aeruginosa (15, 18, 20, 28) . Like carbenicillin, ticarcillin demonstrates in vitro synergy against most strains ofP. aeruginosa combined with gentamicin (28) . Because of the increased in vitro efficacy of ticarcillin as compared with carbenicillin against P. aeruginosa, ticarcillin can be given in approximately one-half the dosage of carbenicillin, thereby lessening the possibility of dose-related side effects (circulatory congestion, hypokalemia, and coagulation dysfunction). Like carbenicillin, however, ticarcillin has little activity against Klebsiella spp. and is inactivated by the beta-lactamase of penicillin-resistant strains of Staphylococcus aureus.
The increased in vitro activity of ticarcillin against P. aeruginosa combined with its potential for less toxicity suggested its use as part of an empiric antibiotic approach for suspected infection in febrile granulocytopenic cancer patients. Ticarcillin was therefore studied in combination with either cephalothin or gentamicin because these two combinations will cover most bacterial infections that occur in this patient population (12, 22) . The 127 patient trials re-ported here represent the largest single institution series utilizing ticarcillin for neutropenic patients with suspected infections.
MATERIALS AND METHODS
The patients were hospitalized at the Baltimore Cancer Research Center (BCRC) and were part of a prospective, randomized evaluation of the International Antimicrobial Therapy Project Group under the sponsorship of the European Organization for Research on Treatment of Cancer; the complete protocol and initial Group results have been published (11, 12) .
Patients were eligible for the present study if their absolute granulocyte count was <1,000/,ul and they had an oral temperature of 38.3°C (101°F) or greater in the absence of an obvious noninfective cause of fever (e.g., blood products or cytotoxic drugs). Before beginning antibiotic therapy, all patients at the BCRC had, at a minimum, the following evaluation (12): (i) complete history and physical examination emphasizing subtle findings of inflammation (22) ; (ii) chest radiograph; (iii) two separate blood cultures; (iv) cultures of clinically relevant sites; (v) urinalysis (usually performed by the attending physician); (vi) surveillance cultures (nose, gingiva, axilla, and perianum) (24) ; and (vii) serum electrolytes, blood urea nitrogen, creatinine, glucose, and a complete blood count including differential. In cases of pneumonia, recognized at fever onset, where sputum samples are of minimal value in these granulocytopenic patients, transtracheal aspiration was performed (depending on bleeding parameters), and if this was unrewarding, the patient underwent transtracheal selective bronchial brushing (2) .
Patients were then randomized to receive one of the following two-drug regimens: ticarcillin-cephalothin, ticarcillin-gentamicin, or cephalothin-gentamicin. As this paper relates to the use of ticarcillin, only those 127 patient trials at the BCRC in which ticarcillin was utilized are reported here. The complete 19-institution Group study will be reported separately.
Each antibiotic was dissolved in 50 ml of 5% dextrose and water and infused separately over approximately 10 to 20 min for each antibiotic. The dosages were: ticarcillin (kindly supplied by Robert L. Vann, Beecham Laboratories, Bristol, Tenn.), 12 g/m2 per day (average, 5 g every 6 h); cephalothin, 7 g/m2 per day (average, 3 g every 6 h); and gentamicin, 180 mg/M2 per day (average, 80 mg every 6 h or 4.5 mg/ kg per day). Antibiotic dosage was adjusted accordingly for renal dysfunction.
Follow-up laboratory evaluations included complete blood count and platelet count four to five times per week. Electrolytes, blood urea nitrogen, creatinine, and SMA-12 were usually performed two to three times per week.
Based on the clinical course and microbiological data, each febrile episode was classified as to whether the infection was: (i) microbiologically documented, (ii) clinically documented, (iii) possible, or (iv) doubtful. The definitions used were substantially the same as those used at this institution since 1969 (25) . Antibiotic response was defined as: (i) improvement (a return of temperature to normal or to the preinfectious state with complete disappearance of all signs and symptoms of infection); (ii) temporary improvement (a return of temperature to normal and resolution of signs and symptoms of infection lasting at least 5 days but followed by a relapse of the same infection either while the patient was still receiving antibiotics or within 1 week after antibiotic discontinuation); (iii) failure (no or poor response to antibiotic therapy); a change of antibiotics or the addition of granulocyte transfusions (21) resulted in the trial being classified as an antibiotic failure regardless of the patient's ultimate clinical course (such changes were made in consultation with the investigators); or (iv) nonevaluable (improvement or no change without any specific relationship to antibiotics). Most patients in this category had febrile episodes that were classified as doubtful. When a patient had a documented viral or fungal infection, the infection was classified as microbiologically documented but nonevaluable in terms of response to the antibiotic regimens (12, 25) .
Antibiotic alteration and changes. The patients with microbiologically documented P. aeruginosa, Klebsiella spp., Enterobacter spp., or Escherichia coli infections were given only the original combination unless the trial was deemed a failure. Nonactive antibiotics were discontinued from the combination once antibiotic susceptibility testing was completed (e.g., cephalothin would be discontinued in a P. aeruginosa infection) (12) . The physician was allowed to substitute methicillin once culture results indicated S. aureus. The infection was considered improved based on the above definitions, provided a response was obvious by the time methicillin was substituted.
If, at the end of 96 h, the patient remained febrile without significant change in the fever pattern, without a site of infection by complete reevaluation, and without positive findings from cultures, then both antibiotics were discontinued and the patient was recultured and observed closely (12) .
Antibiotic susceptibility testing and antibiotic serum levels. Antibiotic susceptibility testing of all isolates was performed by the method of Bauer et al. (3) as recommended by the Food and Drug Administration (9). Ticarcillin disk-resistant gram-negative bacilli were further evaluated by a microtiter technique to determine minimal inhibitory concentrations. Serum levels of ticarcillin and gentamicin were determined for some patients at 1 and 5 h after completion of antibiotic infusion by a modified agar well diffusion method described by Bennett et al. (4) . For ticarcillin, the assay organism was P.
aeruginosa NTCC 10701, which was resistant to gentamicin and cephalothin. For the gentamicin assay, beta-lactamase was added to the serum to destroy the ticarcillin. Thereafter the aminoglycoside concentration was determined by using Bacillus subtilis as the assay organism.
RESULTS
Patient characteristics. There were 62 patient trials with ticarcillin-cephalothin and 65 with ticarcillin-gentamicin ( Table 1) . Both groups were equivalent with regard to age, sex ratio, tumor type (>75% of patients had acute leukemia), and numbers of patients receiving oral nonabsorbable antibiotics or treated in reverse isolation rooms for infection prophylaxis.
Classification, site, and etiology of infection. Of the 127 patient trials, there were 26 (20%) bacteremias, 27 (21%) nonbacteremic microbiologically documented infections, 29 (23%) clinically documented infections, 6 (5%) possible infections, and 39 (31%) episodes where infection was doubtful.
The most common sites of infection were skin and soft tissue (20) , oral lesions (18), perianal lesions (12), urinary tract (8) , colon (8) , lower respiratory tract (7), and nose and sinuses (5) .
The organisms that caused most infections were S. aureus (15) , Klebsiella spp. (12) (Table 3) . Eight of nine (89%) S. aureus bacteremias improved. The one patient listed as not responding had an S. aureus endometritis susceptible to both ticarcillin and gentamicin; the patient improved slowly with the addition of granulocyte transfusions. The patients with gram-negative bacteremias, as a group, did poorly, with only 4 of 15 (27%) showing a complete response without the need for other antibiotics or granulocyte transfusions. Three additional patients had a definite temporary improvement but relapsed shortly thereafter; the remaining eight patients did not respond to initial therapy.
Failure to respond to initial antibiotic therapy usually depended on the type of infection and the patient's current status rather than the specific antibiotic combination. The presence of gram-negative bacteremia was a major adverse prognostic finding (27% improvement rate for gram-negative bacteremia compared with improvement in 89% for S. aureus bacteremias, 88% for nonbacteremic microbiologically documented infections, and 95% for clinically documented infections). Among the 12 antibiotic failures in all categories, poor prognostic indicators included gram-negative bacteremias in eight, mixed organism infections in three, and clinical shock at presentation in two. Only two patients had organisms ultimately found to be resistant to both antibiotics administered. These 12 patients each had a granulocyte count below 500/gl (median, 100/1l; range, 1 to 450); 10 of the 12 had been granulocytopenic for over 30 days, and all 12 patients had aplastic bone marrows at the onset of infection (such that peripheral granulocytes did not begin to return to normal for at least 10 days in any patient). Seven of the 12 patients had progressive neoplasia unresponsive to therapy.
Granulocyte transfusions were given to six of these patients who failed to respond adequately to initial antibiotic therapy. Two died shortly; one began to improve but died of a Torulopsis glabrata pneumonia with sepsis. Two patients had bacteremias caused by resistant organisms (E. coli and S. marcescens, each resistant to ticarcillin, cephalothin, and gentamicin) which improved upon the addition of granulocyte transfusions and institution of polymyxin B.
Finally, one patient with progressive S. aureus endometritis (susceptible to the antibiotic combination that she was receiving) slowly improved after the addition of granulocyte transfusions.
Clinical shock was present in three patients at the time of randomization. One patient had an S. aureus and P. aeruginosa bacteremia associated with a subclavian catheter and died while receiving the first dose of antibiotics (excluded from analysis as nonevaluable). The second patient had an E. coli bacteremia from a perianal lesion caused by both E. coli and P. aeruginosa; he died within 3 days. A third patient with Klebsiella pneumoniae bacteremia from an oral lesion had a temporary improvement to initial intensive measures including empiric ticarcillin plus cephalothin, but ultimately succumbed despite addition of gentamicin and granulocyte transfusions.
Antibiotic susceptibility was not of major importance provided the bacteremia was caused by an organism(s) susceptible to at least one of the two antibiotics in the combination. Among the 15 patients with gram-negative bacteremia, only 2 were infected by an organism resistant to ticarcillin, cephalothin, and gentamicin and hence to the combination administered empirically. Both Side effects. Two patients receiving ticarcillin plus cephalothin and two receiving ticarcillin plus gentamicin developed a rash that was believed related to one of the antibiotics; however, other drugs, notably allopurinol, could not be discounted as either a cause or a potentiator. Two patients receiving ticarcillin plus cephalothin but none receiving ticarcillin plus gentamicin developed a rise in serum creatinine from a normal baseline value (<1.5 mg/ 100 ml) to >1.5 mg/100 ml without any potential cause other than antibiotic administration. Hypokalemia (serum potassium <3.5 meq/liter) occurred in 23% of patients receiving ticarcillin plus cephalothin and 20% receiving ticarcillin plus gentamicin. Serious fluid overload, apparently related to the disodium salt of ticarcillin, occurred only once. One patient, who had preexisting renal dysfunction secondary to multiple myeloma, inadvertently received a full dosage of ticarcillin with subsequent development of a bleeding diathesis characterized by petechiae, ecchymoses, and epistaxis in association with reduced fibrinogen and prolongation of partial thromboplastin and prothrombin times. The serum level of ticarcillin 9 h after the final dose was 1,050 ug/ml; ticarcillin was discontinued and the bleeding diathesis was resolved.
Further infections. Further infections (any infection occurring during antibiotic administration or within 7 days after their discontinuation) occurred in 5 of 62 (8%) ticarcillin-pluscephalothin trials and 13 of 65 (20%) ticarcillinplus-gentamicin trials ( Table 5 ). The further infections with the former regimen included two bacterial and three fungal infections with three deaths; with the latter regimen there were nine bacterial and three fungal infections with four deaths.
Seventeen of the further infections occurred in the patients with documented infections (i.e., prolonged antibiotic therapy), whereas only one of the 19 infection-doubted patients (i.e., 4 days or less of antibiotics) developed a further infection. The median days on antibiotics before a further infection was 11.5. All patients were still granulocytopenic at the onset of further infection.
Infection doubted. Thirty-nine patients (31%) of the entire group were classified as having infection doubted. In some patients the cause offever was rapidly apparent (blood products or chemotherapy), but in many others fever persisted without change during antibiotic administration. In such patients, after com- plete reassessment (history, examination, chest radiograph, and repeat cultures), all antibiotics were discontinued at 96 h and the patient was observed. In this series, only one patient was subsequently proven to have had an infection "masked" by the antibiotic regimen, thus suggesting that it is quite safe to discontinue empiric antibiotics after 96 h provided that a thorough reevaluation fails to disclose infection. This approach can substantially reduce the risk of further infection.
Blood levels. Serum samples were obtained for antibiotic determinations (Table 6 ) at 1 and 5 h after completion of antibiotic infusion. In all cases, ticarcillin was the second of the two antibiotics given. Infusions frequently took more than the planned 20 min per antibiotic. The mean serum level of ticarcillin was 180 ,ug/ml at 1 h and 35 Ag/ml at 5 h. The mean gentamicin serum level was 2.3 ,ug/ml at 1 h and 0.8 ,ug/ ml at 5 h. Cephalothin was not assayed. DISCUSSION Ticarcillin was utilized in these combinations because of its promise based on in vitro studies of being a suitable alternative to carbenicillin for the treatment of organisms such as P. aeruginosa, E. coli, Enterobacter spp., and some strains of Proteus spp. Multiple laboratory evaluations have shown that ticarcillin is more effective on a weight basis than carbenicillin against P. aeruginosa (17, 20) . This allows for use of a lower dosage with potential for fewer dose-related side effects of sodium overload, hypokalemia, and coagulation abnormali- ties. In addition, synergism frequently occurs between ticarcillin and gentamicin when tested against P. aeruginosa (8). The combinations chosen in this study included ticarcillin plus gentamicin because of the activity of ticarcillin and gentamicin together against P. aeruginosa and because gentainicin could be expected to have broad coverage against most of the other organisms, including S. aureus, that might be expected to infect this patient population. The other combination, ticarcillin plus cephalothin, includes ticarcillin for its activity against P. aeruginosa, Enterobacter spp., and many strains of E. coli and Proteus spp. and has cephalothin for activity againstKlebsiella spp., some strains ofE. coli, and S. aureus.
Rodriguez et al. (19) (24) and earlier institution of the empiric antibiotic regimen. The few patients who nevertheless developed a gramnegative bacteremia were among the patients with the most prolonged and persistent granulocytopenia and hence the worst prognosis. The paradoxical result has been a reduced incidence but an increased mortality from gram-negative bacteremia. For similar reasons, only three patients presented with bacteremic shock, but each died rapidly.
For those patients not in shock, early institution of granulocyte transfusions were often lifesaving until bone marrow function could recover (21) . It would appear that granulocyte transfusions are both indicated and essential in patients with gram-negative bacteremia and hypoplastic bone marrows.
The patients with S. aureus infections, including those with bacteremias, fared well on both empiric antibiotic regimens. It must be noted that patients receiving ticarcillin-gentamicin were switched to methicillin alone once the culture results indicated S. aureus as a single infecting organism. This conversion generally occurred on days 3 to 5 of therapy, i.e., at a time when initial response to the initial therapy was apparent. This suggests that even in these high-risk patients, an aminoglycoside such as gentamicin is sufficient early coverage for S. aureus.
Immediate institution of empiric antibiotics is undoubtedly useful in this patient setting, but overuse may lead to further infection. The median time on antibiotics before further infection was 11.5 days. Seventeen of 18 occurred among the patients with documented infection, i.e., those patients who required prolonged antibiotic therapy. Only one of 39 patients with infection doubted (i.e., antibiotics discontinued within 96 h) developed a further infection, emphasizing the importance of limiting unnecessary prolongation of antibiotic therapy.
Side effects from either combination were relatively few in number and included hypokalemia in an equivalent percentage (20 to 23%) with either antibiotic combination. Circulatory congestion occurred once, rash thought possibly to be due to ticarcillin occurred four times, and a coagulation abnormality related to an excessively high blood level of ticarcillin in a patient with azotemia occurred once (8) . These side effects were minimal and suggest that ticarcillin in either combination was relatively safe. Unfortunately, this was not a comparative study with carbenicillin, so no specific comments can be made as to relative degrees of hypokalemia or circulatory overload between ticarcillin and carbenicillin.
Ticarcillin in combination with either cephalothin or gentamicin appears to be safe and efficacious when used in a program of prompt empiric antibiotic therapy for febrile granulocytopenic cancer patients.
